Tazobactum Piperacillin

# Piperacillin/Tazobactam ## Overview - **Classification**: Extended-spectrum penicillin antibiotic combined with a beta-lactamase inhibitor. - **Mechanism**: Piperacillin inhibits bacterial cell wall synthesis. Tazobactam protects piperacillin from degradation by bacterial beta-lactamase enzymes. ## Primary Indications 1. **Intra-abdominal Infections** - Complicated, including appendicitis, peritonitis, abscesses. 2. **Skin and Skin Structure Infections** - Complicated, including cellulitis, abscesses, diabetic foot infections. 3. **Gynecologic Infections** - Postpartum endometritis, pelvic inflammatory disease (PID). 4. **Nosocomial Pneumonia** - Hospital-acquired and ventilator-associated pneumonia (HAP/VAP). 5. **Community-Acquired Pneumonia** - Moderate to severe CAP. 6. **Febrile Neutropenia** - Empiric therapy for fever in neutropenic patients. ## Adult Dosing ### Standard Dosing **Most Indications (e.g., cIAI, cSSTI, Nosocomial Pneumonia)** - **Dose**: **3.375 g** (3g piperacillin/0.375g tazobactam) - **Frequency**: Every **6 hours** - **Route**: IV infusion over 30 minutes (or extended infusion over 3-4 hours) - **Duration**: 5-14 days depending on infection severity and type. **Febrile Neutropenia** - **Dose**: **4.5 g** (4g piperacillin/0.5g tazobactam) - **Frequency**: Every **6 hours** - **Route**: IV infusion over 30 minutes (or extended infusion over 3-4 hours) ### Dose Adjustments - **Renal Impairment**: - CrCl > 40 mL/min: No adjustment. - CrCl 20-40 mL/min: **2.25 g** IV every **6 hours**. - CrCl < 20 mL/min: **2.25 g** IV every **8-12 hours**. - Hemodialysis: **2.25 g** IV every **8-12 hours**; administer one additional dose of **0.75 g** after each dialysis session. - **Hepatic Impairment**: No specific adjustment; use with caution. - **Elderly Patients**: Adjust based on renal function; monitor closely for adverse effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **50-100 mg/kg** (piperacillin component) - **Frequency**: - **<7 days old**: Every **12 hours** - **>7 days old**: Every **8 hours** - **Maximum**: **3.375 g/dose** (limited by adult dosing for severe infections) - **Special Notes**: Consider immature renal function and potential for drug accumulation. Administer over 30 minutes IV. ### Infants (1-12 months) - **Dose**: **80 mg/kg** (piperacillin component) - **Frequency**: Every **6 hours** - **Maximum**: Not to exceed **4.5 g/dose** - **Special Notes**: Administer over 30 minutes IV. ### Children (1-12 years) - **Dose**: **80-100 mg/kg** (piperacillin component) - **Frequency**: Every **6 hours** - **Maximum**: Not to exceed **4.5 g/dose**. Higher doses (up to 300 mg/kg/day) may be used for cystic fibrosis. - **Special Notes**: Administer over 30 minutes IV. ### Adolescents (13-18 years) - **Dose**: Use **adult dosing** as described above. - **Maximum**: **4.5 g/dose**, not to exceed **18 g/day**. ## Safety Information ### Contraindications - **Absolute**: History of severe hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to piperacillin, tazobactam, or other beta-lactam antibiotics (penicillins, cephalosporins). ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea, headache, nausea, constipation, rash. - **Common (1-10%)**: Vomiting, dyspepsia, insomnia, elevated LFTs, phlebitis at injection site, candidiasis. - **Serious but Rare**: Anaphylaxis, Clostridioides difficile-associated diarrhea (CDAD), seizures, leukopenia, thrombocytopenia, hemolytic anemia, interstitial nephritis. ### Key Drug Interactions - **Probenecid**: Increases and prolongs piperacillin levels. Co-administration not generally recommended. - **Vecuronium/Other Neuromuscular Blockers**: Prolongs neuromuscular blockade; monitor patients closely. - **Methotrexate**: Reduces methotrexate clearance, increasing toxicity. Monitor methotrexate levels and signs of toxicity. - **Warfarin**: May alter coagulation parameters (prolong PT/INR). Monitor INR closely. - **Vancomycin**: Increased risk of acute kidney injury (AKI) when co-administered. Monitor renal function closely. ## Monitoring & Follow-up - **Before Treatment**: Culture & susceptibility results (if available), renal function (SCr, CrCl), hepatic function (LFTs), CBC with differential. - **During Treatment**: Renal function (SCr, CrCl) daily or every 2-3 days, CBC with differential (especially with prolonged therapy or high doses), LFTs periodically, signs of superinfection. - **Clinical Signs**: Resolution of infection symptoms, signs of hypersensitivity reaction (rash, dyspnea), signs of CDAD (diarrhea), signs of neurotoxicity (seizures). ## Clinical Pearls - 💡 **Tip 1**: Extended infusion (e.g., 3-4 hours) is often preferred for critically ill patients to optimize pharmacodynamics (time above MIC) and improve outcomes. - 💡 **Tip 2**: Always confirm penicillin allergy history. Differentiate between true IgE-mediated reactions and minor rashes. - 💡 **Tip 3**: Monitor for Clostridioides difficile-associated diarrhea (CDAD), particularly with prolonged use or in high-risk patients. - 💡 **Tip 4**: Contains significant sodium (~2.35 mEq Na per gram of piperacillin); consider in patients with fluid restrictions or heart failure. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.